- Home
- WDH vs OVID Comparison
WDH vs OVID Comparison
Compare WDH & OVID Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | WDH | OVID |
|---|---|---|
| Founded | 2016 | 2014 |
| Country | China | United States |
| Employees | 3018 | N/A |
| Industry | Specialty Insurers | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 362.9M | 421.8M |
| IPO Year | 2020 | 2017 |
Fundamental Metrics
Financial Performance| Metric | WDH | OVID |
|---|---|---|
| Price | $1.00 | $2.55 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 4 | 13 |
| Target Price | $1.73 | ★ $6.40 |
| AVG Volume (30 Days) | 228.1K | ★ 1.7M |
| Earning Date | 12-02-2026 | 11-11-2026 |
| Dividend Yield | ★ 5.94% | N/A |
| EPS Growth | N/A | ★ 3.90 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $7,252,000.00 |
| Revenue This Year | $27.14 | N/A |
| Revenue Next Year | $34.64 | N/A |
| P/E Ratio | $9.00 | ★ N/A |
| Revenue Growth | N/A | ★ 1181.27 |
| 52 Week Low | $0.96 | $1.18 |
| 52 Week High | $2.03 | $3.11 |
Technical Indicators
Market Signals| Indicator | WDH | OVID |
|---|---|---|
| Relative Strength Index (RSI) | 42.98 | 56.21 |
| Support Level | $0.97 | $2.51 |
| Resistance Level | $1.02 | $2.84 |
| Average True Range (ATR) | 0.02 | 0.20 |
| MACD | -0.00 | 0.04 |
| Stochastic Oscillator | 28.57 | 75.41 |
Price Performance
Historical ComparisonAbout WDH Waterdrop Inc. (each representing the right to receive 10)
Waterdrop Inc is a technology platform dedicated to insurance and healthcare service. The Company is mainly engaged in operating an independent third-party insurance platform dedicated to providing insurance and healthcare service. The Companies main businesses are the insurance marketplace, medical crowdfunding, and mutual aid. The companies reportable segments are Insurance, Crowdfunding and Others.
About OVID Ovid Therapeutics Inc.
Ovid Therapeutics Inc is a biopharmaceutical company that is dedicated to reducing seizures and meaningfully improving the lives of people affected by rare epilepsies and seizure-related neurological disorders. The company has built a differentiated pipeline of medicines with potential first-in-class drug mechanisms of action to treat seizures. This pipeline has produced two epilepsy programs with potential first-in-class mechanisms of action, and one epilepsy program with a potential best-in-class mechanism of action.